Kamada Ltd. (NASDAQ:KMDA) Short Interest Up 2,002.5% in February

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) was the target of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 166,100 shares, a growth of 2,002.5% from the January 31st total of 7,900 shares. Currently, 0.5% of the company's shares are short sold. Based on an average trading volume of 175,600 shares, the short-interest ratio is currently 0.9 days.

Kamada Stock Down 1.5 %

KMDA stock traded down $0.10 during midday trading on Monday, hitting $6.79. The company's stock had a trading volume of 107,653 shares, compared to its average volume of 270,284. Kamada has a 52-week low of $4.74 and a 52-week high of $9.15. The firm has a 50-day simple moving average of $7.03 and a 200-day simple moving average of $6.12. The firm has a market capitalization of $390.29 million, a P/E ratio of 24.25, a PEG ratio of 0.97 and a beta of 0.99.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and set a $11.00 price objective on shares of Kamada in a research report on Friday, January 10th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in KMDA. Plato Investment Management Ltd acquired a new stake in shares of Kamada in the 3rd quarter valued at $117,000. Public Employees Retirement System of Ohio purchased a new stake in Kamada during the 3rd quarter worth about $77,000. JPMorgan Chase & Co. acquired a new position in shares of Kamada during the 4th quarter worth about $67,000. NewEdge Advisors LLC increased its holdings in shares of Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock valued at $143,000 after acquiring an additional 8,260 shares during the last quarter. Finally, Aristides Capital LLC increased its holdings in shares of Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock valued at $387,000 after acquiring an additional 6,850 shares during the last quarter. Hedge funds and other institutional investors own 20.38% of the company's stock.

Remove Ads

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.